SARS-CoV-2 Mutation Assay Panel
Reflex-free detection of Variants of Concern
SARS-CoV-2, like all RNA viruses, evolves and mutates. Since its discovery, the viral sequence for the novel coronavirus has accumulated a staggering number of mutations, giving rise to more virulent, transmissible and deadly variations that are taking hold across the globe. Since the virus can evolve, the assays designed to detect it must evolve as well.
The Fluidigm RT-PCR based Advanta® SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
Product Highlights
-
Reflex-free workflow: Detects SARS-CoV-2 and key mutations concurrently from the same input sample on one IFC, saving reagents, samples and time
-
Saliva-based and extraction-free: Performs equivalently to comparator nasal tests utilizing convenient and noninvasive sample collection without the need for commercial extraction kits
-
More valuable data: Supports detection and surveillance of key mutations from a single high-throughput workflow that supports up to 6,000 samples per day
-
Flexible: Enables convenient addition of mutations emerging in the future, unlike other multiplex RT-PCR assays, due to the open architecture of the IFC
Panel Layout
|
N1 |
N2 |
RNase P |
|
N1 |
N2 |
RNase P |
|
N1 |
N2 |
RNase P |
|
N1 |
N2 |
RNase P |
|
L452R mutant |
K417N mutant |
N501Y mutant |
|
L452R wild type |
K417N wild type |
N501Y wild type |
|
∆69/70 mutant |
K417T mutant |
E484K mutant |
|
∆69/70 wild type |
K417T wild type |
E484K wild type |
The Mutation Assay expands on our current pathogen detection portfolio by concurrently detecting SARS-CoV-2 N1 and N2 genes and probe pairs to independently target both the wild type and mutation of each allele of the virus.
|
Mutation |
B.1.1.7 |
B.1.351 |
P.1 |
B.1.427 |
B.1.526 |
B.1.617.2 |
|
WHO Identification |
Alpha |
Beta |
Gamma |
Epsilon |
Iota |
Delta |
|
K417N |
|
X |
|
|
|
|
|
K417T |
|
|
X |
|
|
|
|
L452R |
|
|
|
X |
|
X |
|
E484K |
|
X |
X |
|
X |
|
|
N501Y |
X |
X |
X |
|
|
|
|
∆69/70 |
X |
|
|
|
|
|
The mutations chosen for this panel align with current CDC and WHO Variants of Concern.
Advanta SARS-CoV-2 Mutation Assay Panel workflow total instrument run time <3 hours
New tech note for Delta and Delta+ variants using Advanta SARS-CoV-2 Mutation Assay Panel
Learn more about the assay.
Detect mutations associated with Variants of Concern
Dr. Dexi Chen, PhD, MD
Achieving multi-omic insights with microfluidics and CyTOF technology
Dr. Luc Teyton, MD, PhD
How one lab explores the immune system one T cell at a time
Scott Magness, PhD
Investigating transcriptomic changes at the microscale level
Simone Mayer, PhD
Simone Mayer, PhD, explains how using multimodal analysis helped reveal new insights
Jo Vandesompele, PhD
Jo Vandesompele at Ghent University discusses a deep dive into single-cell sequencing
Christophe Lancrin, PhD
Christophe Lancrin on revealing new transcription factors using C1 and Biomark
For Research Use Only. Not for use in diagnostic procedures. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. All rights reserved.